Redistribution of accumulated 2,3,7,8-tetrachlorodibenzo-p-dioxin during coxsackievirus B3 infection in the mouse

Toxicology Letters

Volumn 116, Issue 1-2, 2000, Pages 131-141

  Funseth, Eva ^a   Wicklund Glynn, Anders ^a,b   Friman, Göran ^a   Ilbäck, Nils Gunnar ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b NATIONAL FOOD ADMINISTRATION   (Sweden)

Author keywords

2,3,7,8 tetrachlorodibenzo p dioxin; Infection; Tissue redistribution

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; ENVIRONMENTAL EXPOSURE; HEART; INFLAMMATION; LIVER; MALE; MOUSE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; SCINTILLATION; STORAGE; TARGET ORGAN; THYMUS; TISSUE; TISSUE DISTRIBUTION; WHITE ADIPOSE TISSUE;

ANIMALS; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; MALE; MICE; TETRACHLORODIBENZODIOXIN; TISSUE DISTRIBUTION;

COXSACKIEVIRUS;

EID: 0033947242     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(00)00217-4     Document Type: Article

References (36)

1. Beisel, K.W., Traystman, M.D., 1988. Viral myocarditis: immunogrenetic and autoimmune aspects. In: Schultheiß, H.-P. (Ed.), New concepts in viral heart disease. Springer Verlag, Berlin, pp. 140-159.
2. Beisel, W.R., 1998. Metabolic response of the host to infections. In: Feigin, R.D., Cherry J.D. (Eds.), Textbook of pediatric infectious diseases, fourth ed. W.B. Saunders, Philadelphia, pp. 54-69.
3. Beck M.A., Kolbeck P.C., Shi Q., Morris C.V., Levander O.A. Increased virulence of a human enterovirus (Coxsackievirus B3) in selenium-deficient mice. J. Infect. Dis. 170:1994;351-357.
4. Darnerud P.-O., Törnwall U., Bergman Å., Brandt I. Liver accumulation of 2,3,7,8-tetrachlorodibenzofuran in mice: modulation by treatments with polychlorinated biphenyls. Chem.-Biol. Interact. 89:1993;89-102.
5. Diliberto J.J., Akubue P.I., Luebke R.W., Birnbaum L.S. Dose-response relationships of tissue distribution and induction of CYP1A1 and CYP1A2 enzymatic activities following acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice. Toxicol. Appl. Pharmacol. 130:1995;197-208.
6. Diliberto J.J., Burgin D., Birnbaum L.S. Role of CYP1A2 in hepatic sequestration of dioxin: studies using CYP1A2 knock-out mice. Biochem. Biophys. Res. Commun. 236:1997;431-433.
7. de Waal E.-J., Schuurman H.-J., Loeber J.G., van Loveren H., Vos J.G. Alterations in the cortical thymic epithelium of rats after in vivo exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): an (immuno)histological study. Toxicol. Appl. Pharmacol. 115:1992;80-88.
8. FADL, 1989. Environmental Health Series 34, Levels of PCBs, PCDDs and PCDFs in breast milk: results of WHO-coordinated interlaboratory quality control studies and analytical field studies, WHO, Copenhagen, pp. 1-92.
9. Funseth E., Ilbäck N.-G. Coxsackievirus B3 infection alters the uptake of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the mouse. Toxicology. 90:1994;29-38.
10. Gallin, J.I., 1993. Inflammation. In: Paul, W.E. (Ed.), Fundamental immunology, third ed. Raven Press, New York, pp. 1015-1032.
11. Ghezzi P., Saccardo B., Villa P., Rossi V., Bianchi M., Dinarello C.A. Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect. Immun. 54:1986;837-840.
12. Goldstein J.A., Linko P. Differential induction of two 2,3,7,8-tetrachlorodibenzo-p-dioxin inducible forms of cytochrome P-450 in extrahepatic versus hepatic tissues. Mol. Pharmacol. 25:1983;185-191.
13. Huber, S.A. 1993. Animal models: immunological aspects. In: Banatvala, J.E. (Ed.), Viral infections of the heart. Hodder and Stoughton, London, pp. 82-109.
14. Huber S.A., Gauntt C.J., Sakkinen P. Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction and immunopathogenicity. Adv. Virus Res. 51:1999;35-80.
15. Ilbäck N.-G., Fohlman J., Friman G. The protective effect of selenium on the development of coxsackievirus B3 induced inflammatory lesions in the murine myocardium. J. Trace Elem. Exp. Med. 2:1989;257-266.
16. Ilbäck N.-G., Wesslén L., Pauksen K., Stålhandske T., Friman G., Fohlman J. Effects of the antiviral WIN 54 954 and the immune modulator LS 2616 on cachectin/TNF and γ-interferon responses during viral heart disease. Scand. J. Infect. Dis. Suppl. 88:1993;117-123.
17. Ilbäck N.-G., Fohlman J., Friman G. Changed distribution and immune effects of nickel augment viral-induced inflammatory heart lesions in mice. Toxicology. 91:1994;203-219.
18. Ilbäck N.-G., Lindh U., Fohlman J., Friman G. New aspects from murine Coxsackie B3 myocarditis-focus on heavy metals. Eur. Heart J. 16:1995;20-24.
19. IPCS, 1989. Environmental Health Criteria 88, Polychlorinated dibenzo-p-dioxins and dibenzofurans. WHO, Geneva, pp. 17-22.
20. Kainu T., Gustafsson J.Å., Pelto-Huikko M. The dioxin receptor and it′s nuclear translocator (Arnt) in the rat brain. NeuroReport. 6:1995;2557-2560.
21. Kerkvliet N.I. Immunological effects of chlorinated dibenzo-p-dioxins. Environ. Health Perspect. 103:1995;47-53.
22. Khatib R., Chason J.L, Silberberg B.K., Lerner A.M. Age-dependent pathogenicity of group B coxsackieviruses in Swiss-Webster mice: infectivity for myocardium and pancreas. J. Infect. Dis. 141:1980;394-403.
23. Leung H.-W., Wendling J.M., Orth R., Hileman F., Paustenbach D.J. Relative distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human hepatic and adipose tissue. Toxicol. Lett. 50:1990;275-282.
24. Luebke R.W., Copeland C.B., Diliberto J.J., Akubue P.I., Andrews D.L., Riddle M.M., Williams W.C., Birnbaum L.S. Assessment of host resistance to Trichinella spiralis in mice following preinfection exposure to 2,3,7,8-TCDD. Toxicol. Appl. Pharmacol. 12:1994;7-16.
25. Matsumori, A., 1993. Animal models: pathological findings and therapeutic considerations. In: Banatvala, J.E. (Ed.), Viral infections of the heart. Hodder and Stoughton, London, pp. 110-137.
26. Maisch, B., Herzum, M., Schönian, U., 1993. Pathogenesis of disease: humans. In: Banatvala, J.E. (Ed.), Viral infections of the heart. Hodder and Stoughton, London, pp. 138-175.
27. Morgan E.T. Regulation of cytochromes P-450 during inflammation and infection. Drug Metab. Rev. 29:1997;1129-1188.
28. Neal R.A., Olson J.R., Gasiewicz T.A., Geiger L.E. The toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mammalian systems. Drug Metab. Rev. 13:1982;355-385.
29. Nebert D.W., Jensen N.M., Shinozuka H., Kunz H.W., Gill T.J. The AH-phenotype. Survey of 48 rat strains and 20 inbred mouse strains. Genetics. 100:1982;79-87.
30. Poiger H., Schlatter C. Pharmacokinetics of 2,3,7,8-TCDD in man. Chemosphere. 15:1986;1489-1494.
31. 14C-TCDD in a TCDD-susceptible and a TCDD-resistant rat strain. Pharmacol. Toxicol. 66:1990;93-100.
32. Renton K.W. Depression of hepatic cytochrome P-450-dependent mixed function oxidase during infection with encephalomyocarditis virus. Biochem. Pharmacol. 30:1981;2333-2336.
33. van Miller J.P., Marlar R.J., Allen J.R. Tissue distribution and excretion of tritiated tetrachlorodibenzo-p-dioxin in non-human primates and rats. Fd. Cosmet. Toxicol. 14:1976;31-34.
34. Wang X., Santostefano M.J., Evans M.V., Richardson V.M., Diliberto J.J., Birnbaum L.S. Determination of parameters responsible for pharmacokinetic behaviour of TCDD in female Sprague-Dawley rats. Toxicol. Appl. Pharmacol. 147:1997;151-168.
35. Woodruff J.F., Kilbourne E.D. The influence of quantitated post weaning undernutrition in Coxsackievirus B3-infection of adult mice. I. Viral persistence and increased severity of lesions. J. Infect. Dis. 121:1970;137-163.
36. Woodruff J.F. Viral myocarditis. A review. Am. J. Pathol. 101:1980;424-479.